Kestra Showcases Real-World Outcomes for ASSURE WCD at Heart Rhythm 2025
Kestra Medical Technologies presented new real-world data for their ASSURE Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025 in San Diego. The study focused on outcomes in a community-based setting using an advanced practice provider (APP)-driven protocol.
Key findings demonstrate:
- High patient compliance with 23.3 hours median daily wear time
- Consistent usage beyond 90 days
- 4% of patients showed ventricular arrhythmias detection
- Successful implementation of APP-driven care model
- Effective continuity of care through ICD placement or hospitalization when needed
The study validates ASSURE's effectiveness in protecting patients from sudden cardiac arrest through both clinical performance and patient engagement. The results highlight the success of structured, team-based approaches in expanding access to cardiac care within community settings.
Kestra Medical Technologies ha presentato nuovi dati reali riguardanti il loro Defibrillatore Cardioversore Indossabile (WCD) ASSURE al congresso Heart Rhythm 2025 a San Diego. Lo studio si è concentrato sui risultati ottenuti in un contesto comunitario utilizzando un protocollo gestito da operatori sanitari avanzati (APP).
I risultati principali mostrano:
- Elevata compliance dei pazienti con un tempo medio di utilizzo giornaliero di 23,3 ore
- Uso costante oltre i 90 giorni
- Il 4% dei pazienti ha manifestato rilevamento di aritmie ventricolari
- Implementazione efficace del modello di cura guidato dagli APP
- Continuità di cura efficace tramite posizionamento di ICD o ricovero ospedaliero quando necessario
Lo studio conferma l’efficacia di ASSURE nel proteggere i pazienti dall’arresto cardiaco improvviso, sia attraverso le prestazioni cliniche che l’impegno dei pazienti. I risultati evidenziano il successo di approcci strutturati e di team nel facilitare l’accesso alle cure cardiache in ambito comunitario.
Kestra Medical Technologies presentó nuevos datos del mundo real sobre su Desfibrilador Cardioversor Vestible (WCD) ASSURE en Heart Rhythm 2025 en San Diego. El estudio se centró en resultados en un entorno comunitario utilizando un protocolo dirigido por proveedores de práctica avanzada (APP).
Los hallazgos clave demuestran:
- Alta adherencia de los pacientes con un tiempo medio diario de uso de 23,3 horas
- Uso constante más allá de los 90 días
- El 4% de los pacientes mostró detección de arritmias ventriculares
- Implementación exitosa del modelo de atención dirigido por APP
- Continuidad efectiva de la atención mediante la colocación de ICD o hospitalización cuando fue necesario
El estudio valida la efectividad de ASSURE para proteger a los pacientes del paro cardíaco súbito, tanto por su desempeño clínico como por la participación del paciente. Los resultados destacan el éxito de enfoques estructurados y en equipo para ampliar el acceso a la atención cardíaca en entornos comunitarios.
Kestra Medical Technologies가 샌디에이고에서 열린 Heart Rhythm 2025에서 ASSURE 착용형 심장충격기(WCD)에 대한 실제 데이터 신뢰성을 발표했습니다. 본 연구는 고급 실무 제공자(APP) 주도 프로토콜을 활용한 지역사회 기반 환경에서의 결과에 초점을 맞추었습니다.
주요 발견 내용은 다음과 같습니다:
- 환자의 높은 순응도, 하루 평균 착용 시간 23.3시간
- 90일 이상 지속적인 사용
- 4% 환자에서 심실성 부정맥 검출
- APP 주도 진료 모델의 성공적 도입
- 필요 시 ICD 이식 또는 입원을 통한 효과적인 연속 치료
본 연구는 ASSURE가 임상 성능과 환자 참여를 통해 돌연 심장정지를 예방하는 데 효과적임을 입증합니다. 결과는 지역사회 환경에서 심장 치료 접근성을 확대하는 구조화된 팀 기반 접근법의 성공을 강조합니다.
Kestra Medical Technologies a présenté de nouvelles données issues du monde réel concernant leur Défibrillateur Cardioverteur Portable (WCD) ASSURE lors du congrès Heart Rhythm 2025 à San Diego. L’étude s’est focalisée sur les résultats dans un cadre communautaire en utilisant un protocole piloté par des praticiens avancés (APP).
Les résultats clés montrent :
- Une forte adhésion des patients avec un temps moyen de port quotidien de 23,3 heures
- Une utilisation constante au-delà de 90 jours
- 4 % des patients ont présenté une détection d’arythmies ventriculaires
- Une mise en œuvre réussie du modèle de soins piloté par les APP
- Une continuité efficace des soins via la pose d’un ICD ou une hospitalisation si nécessaire
L’étude confirme l’efficacité d’ASSURE pour protéger les patients contre l’arrêt cardiaque soudain, à la fois par ses performances cliniques et l’engagement des patients. Les résultats soulignent le succès des approches structurées et en équipe pour élargir l’accès aux soins cardiaques en milieu communautaire.
Kestra Medical Technologies präsentierte neue Real-World-Daten zu ihrem ASSURE Wearable Cardioverter Defibrillator (WCD) auf der Heart Rhythm 2025 in San Diego. Die Studie konzentrierte sich auf Ergebnisse in einer gemeindebasierten Umgebung unter Verwendung eines von Advanced Practice Providern (APP) gesteuerten Protokolls.
Wesentliche Erkenntnisse zeigen:
- Hohe Patienten-Compliance mit einer medianen täglichen Tragezeit von 23,3 Stunden
- Konsequente Nutzung über 90 Tage hinaus
- 4 % der Patienten zeigten Erkennung ventrikulärer Arrhythmien
- Erfolgreiche Implementierung des APP-gesteuerten Versorgungsmodells
- Effektive Kontinuität der Versorgung durch ICD-Implantation oder Krankenhausaufenthalt bei Bedarf
Die Studie bestätigt die Wirksamkeit von ASSURE beim Schutz der Patienten vor plötzlichem Herzstillstand durch klinische Leistung und Patientenengagement. Die Ergebnisse heben den Erfolg strukturierter, teamorientierter Ansätze hervor, um den Zugang zur Herzversorgung in Gemeinschaftsumgebungen zu erweitern.
- High patient compliance with 23.3 hours median daily wear time demonstrates strong product adoption
- Successful arrhythmia detection in 4% of patients validates product effectiveness
- APP-driven care model proves scalability in community settings, potentially reducing operational costs
- Evidence of effective continuity of care through successful patient transitions to ICD placement
- Strong real-world data supporting product performance could drive market adoption
- None.
Insights
Kestra's ASSURE device shows exceptional 23.3-hour daily patient compliance with meaningful arrhythmia detection, validating its effectiveness in community settings.
The real-world data presented on Kestra's ASSURE® Wearable Cardioverter Defibrillator reveals impressive clinical utility metrics that strengthen its value proposition. Patient compliance data showing a median daily wear time of 23.3 hours is remarkable for a wearable device, addressing one of the fundamental challenges in this category. This high compliance rate directly correlates with the device's ability to provide continuous protection.
The 4% ventricular arrhythmia detection rate, even in a predominantly primary prevention population, validates the core monitoring functionality. Most medical devices struggle to demonstrate such clear clinical utility in real-world settings outside controlled trials. The study also highlighted sustained usage beyond 90 days for many patients, demonstrating the device's long-term acceptability.
Perhaps most significant from a healthcare delivery perspective is the validation of an advanced practice provider (APP)-driven care model. This approach could substantially expand the addressable market by enabling deployment through mid-level practitioners rather than solely through cardiologists - potentially addressing specialist bottlenecks in community settings. The documented continuity of care with appropriate escalation to ICD placement or hospitalization demonstrates the ASSURE system's successful integration into established treatment pathways.
Kestra's real-world data showcases exceptional patient engagement with 23.3 hours daily wear time and successful APP-driven implementation model.
The data presented by Kestra Medical Technologies represents an important validation of their connected cardiac monitoring platform in community care settings. The 23.3 hours median daily wear time significantly outperforms typical compliance rates for wearable health technologies. This level of patient engagement is a critical differentiator in the digital health space, where user abandonment frequently undermines clinical effectiveness.
The successful implementation of an advanced practice provider-driven protocol demonstrates that Kestra's technology can be effectively deployed through non-specialist providers. This has substantial implications for scalability, as it suggests the ASSURE system can function within team-based care models that don't rely exclusively on cardiologists, potentially expanding access in underserved communities.
The detection of ventricular arrhythmias in 4% of patients validates the system's monitoring capabilities in a real-world community setting. The documented continuity of care for patients who received therapy - through timely transitions to ICD placement or hospitalization - demonstrates effective integration with existing care pathways. This integration is essential for long-term clinical adoption and sustained utilization.
As healthcare continues to shift toward distributed care models, technologies that can demonstrate effectiveness outside specialized academic centers become increasingly valuable in expanding access while maintaining quality standards.
New data highlights strong wear compliance, meaningful arrhythmia detection, and continuity of care in community-based advanced practice provider-driven model
KIRKLAND, Wash., April 29, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, today announced the presentation of new real-world data on the ASSURE® Wearable Cardioverter Defibrillator (WCD) at Heart Rhythm 2025, the annual meeting of the Heart Rhythm Society (HRS), held April 24–27 in San Diego.
The abstract, titled “Real-world Experience with a Novel Wearable Cardioverter Defibrillator in a Community Setting: Advanced Practice Provider-Driven Care Model,” was developed in partnership with Ashley L. Dailey, ANP-BC, MSN and Opesanmi O. Esan, MD, and presented at the annual meeting. The abstract examined outcomes in a nonprofit, community-based medical center using an advanced practice provider (APP)-driven protocol for WCD therapy—one of the first analyses of its kind.
“The data reinforce how the ASSURE system supports meaningful protection from sudden cardiac arrest through both clinical performance and patient engagement—particularly in real-world, community care settings,” said Brian Webster, President and Chief Executive Officer of Kestra. “We were proud to see this work highlighted at HRS.”
Key Findings from the Abstract
The analysis revealed high patient compliance, with a median daily wear time of 23.3 hours and consistent usage, often extending beyond 90 days—highlighting the importance of sustained device use in protecting patients at risk of sudden cardiac death.
Notably, ventricular arrhythmias were detected in
Additionally, the study highlighted how an APP-driven care model successfully delivered WCD therapy in alignment with guideline-based recommendations—ensuring that all indicated patients received appropriate care and demonstrating the value of structured, team-based approaches in expanding access and improving outcomes within a community-based setting. View the full abstract here.
The presentation marked another milestone for Kestra and its mission to expand access to intelligent, connected cardiac recovery solutions across all levels of care.
About Kestra
Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. For more information, please visit www.kestramedical.com.
Media contact Rhiannon Pickus rhiannon.pickus@kestramedical.com Investor contact Neil Bhalodkar neil.bhalodkar@kestramedical.com
FAQ
What are the key results from Kestra's ASSURE WCD study presented at Heart Rhythm 2025?
How effective is the ASSURE Wearable Cardioverter Defibrillator in real-world settings?
What makes Kestra's (KMTS) ASSURE WCD different in community-based healthcare?
What is the patient compliance rate for Kestra's ASSURE Wearable Cardioverter Defibrillator?
How does Kestra's ASSURE WCD support sudden cardiac arrest prevention?
